Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1966 3
1967 1
1968 4
1970 3
1971 2
1972 2
1973 2
1974 9
1975 1
1976 1
1977 2
1979 3
1980 2
1981 7
1982 7
1983 8
1984 2
1985 6
1986 7
1987 4
1988 8
1989 7
1990 6
1991 8
1992 7
1993 12
1994 14
1995 11
1996 12
1997 13
1998 11
1999 8
2000 11
2001 15
2002 20
2003 26
2004 25
2005 18
2006 26
2007 23
2008 23
2009 29
2010 31
2011 28
2012 26
2013 31
2014 21
2015 34
2016 24
2017 32
2018 33
2019 28
2020 48
2021 45
2022 48
2023 41
2024 44

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

846 results

Results by year

Filters applied: . Clear all
Page 1
[Mucositis].
Sato A, Sakashita A, Taguchi S. Sato A, et al. Among authors: taguchi s. Nihon Rinsho. 2003 Jun;61(6):959-65. Nihon Rinsho. 2003. PMID: 12806943 Review. Japanese.
Angiotensin II type 1 receptor-associated protein in immune cells: a possible key factor in the pathogenesis of visceral obesity.
Tsukamoto S, Suzuki T, Wakui H, Uehara T, Ichikawa J, Okuda H, Haruhara K, Azushima K, Abe E, Tanaka S, Taguchi S, Hirota K, Kinguchi S, Yamashita A, Tamura T, Tamura K. Tsukamoto S, et al. Among authors: taguchi s. Metabolism. 2023 Dec;149:155706. doi: 10.1016/j.metabol.2023.155706. Epub 2023 Oct 13. Metabolism. 2023. PMID: 37856903
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Int J Urol. 2023 Dec;30(12):1180-1186. doi: 10.1111/iju.15300. Epub 2023 Sep 22. Int J Urol. 2023. PMID: 37740409
Combination of sacubitril/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome.
Tsukamoto S, Wakui H, Uehara T, Shiba Y, Azushima K, Abe E, Tanaka S, Taguchi S, Hirota K, Urate S, Suzuki T, Yamada T, Kinguchi S, Yamashita A, Tamura K. Tsukamoto S, et al. Among authors: taguchi s. Eur Heart J Open. 2023 Sep 29;3(6):oead098. doi: 10.1093/ehjopen/oead098. eCollection 2023 Nov. Eur Heart J Open. 2023. PMID: 37941728 Free PMC article.
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Immunotherapy. 2023 Aug;15(11):827-837. doi: 10.2217/imt-2023-0028. Epub 2023 May 16. Immunotherapy. 2023. PMID: 37191002
[AUTOTRANSPLANTATION FOR IATROGENIC URETERAL INJURY FOLLOWING GYNECOLOGICAL SURGERY].
Kinoshita A, Yamada D, Honda K, Danno T, Tokunaga M, Miyakawa J, Taguchi S, Akiyama Y, Yamada Y, Sato Y, Kume H. Kinoshita A, et al. Among authors: taguchi s. Nihon Hinyokika Gakkai Zasshi. 2022;113(4):147-151. doi: 10.5980/jpnjurol.113.147. Nihon Hinyokika Gakkai Zasshi. 2022. PMID: 37866936 Free article. Japanese.
846 results